Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma

Journal of Veterinary Internal Medicine

Volumn 21, Issue 6, 2007, Pages 1231-1236

  Nielsen, Lise ^a   Toft, Nils ^b   Eckersall, P David ^c   Mellor, Dominic J ^c   Morris, Joanna S ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Danish Meat Association   (Denmark)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Acute phase protein; C reactive protein; Complete remission; Serum markers

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; DOG; DOG DISEASE; LYMPHATIC LEUKEMIA; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOG DISEASES; DOGS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANIMALIA; CANIS FAMILIARIS;

EID: 37349075110     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/07-058.1     Document Type: Article

References (44)

1. Dorn CR, Taylor TO, Scheider R, et al. Survey of animal neoplasms in Alameda Contra Costa counties, California II. Cancer morbidity in dogs and cats from Alameda County. J Natl Can Inst 1968;40:307-318.
2. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
3. Kiupel M, Teske E, Bostock D. Prognostic factors for treated canine malignant lymphoma. Vet Pathol 1999;36:292-300.
4. Dobson JM, Blackwood LB, McInnes EF, et al. Prognostic variables in canine multicentric lymphoma. J Small Anim Pract 2001;42:377-384.
5. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-1728.
6. Williams LE, Broussard MT, Johnson JL, Neel J. Comparison of results of clinicians' assessments, cytologic examination of fine-needle lymph node aspirates, and flow cytometry for determination of remission status of lymphoma in dogs. J Am Vet Med Assoc 2005;226:562-566.
7. Ristamaki R, Joensuu H, Hagberg H, et al. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma. Int J Cancer 1998;79:221-225.
8. Stasi R, Zinzani L, Galieni P, et al. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 1995;54:9-17.
9. Kodama J, Miyagi Y, Seki N, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;82:107-110.
10. Ikeda T, Kawakami K, Fujita J, et al. Thymic carcinoma associated with a high serum level of interleukin 6 diagnosed through the evaluation for asymptomatic elevation of acute-phase reactants. Intern Med 1998;37:414-416.
11. Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 1999;35:106-110.
12. Zaloudik J, Lauerova L, Janakova L, et al. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver. Hepatogastroenterology 1999;46:220-227.
13. Inoue T, Hashimura T, Iwamura H, et al. Multivariate analysis of prognostic determinants after surgery for renal cell carcinoma at Himeji National Hospital. Hinyokika Kiyo 2000;46:229-234.
14. Biro L, Domjan G, Falus A, et al. Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest 1998;28:679-686.
15. Wieland A, Kerbl R, Berghold A, et al. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol 2003;41:21-25.
16. Child JA, Cooper EH, Illingworth S, Worthy TS. Biochemical markers in Hodgkin's disease and non-Hodgkin's lymphoma. Recent Results Cancer Res 1978;64:180-189.
17. Legouffe ERC, Picot MC, Richard B, et al. C-reactive protein serum level is a valuable and simple prognostic marker in Non Hodgkin's lymphoma. Leukemia Lymphoma 1998;31:351-357.
18. Martinez-Subiela S, Bernal LJ, Ceron JJ. Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment. Am J Vet Res 2003;64:1021-1026.
19. Onishi T, Inokuma H, Ohno K, et al. C-reactive protein concentrations in normal and diseased dogs - measured by laser nephelometric immunoassay. J Jpn Vet Med Assoc 2000;53:595-601.
20. Tecles F, Spiranelli E, Bonfanti U, et al. Preliminary studies of serum acute-phase protein concentrations in hematologic and neoplastic diseases of the dog. J Vet Intern Med 2005;19:865-870.
21. Rikihisa Y, Yamamoto S, Kwak I, et al. C-reactive protein and alpha 1-acid glycoprotein levels in dogs infected with Ehrlichia canis. J Clin Microbiol 1994;32:912-917.
22. Yamamoto S, Shida T, Miyaji S, et al. Changes in serum C-reactive protein levels in dogs with various disorders and surgical traumas. Vet Res Commun 1993;17:85-93.
23. McGrotty YL, Knottenbelt CM, Ramsey IK, et al. Evaluation of a rapid assay for canine C-reactive protein. Vet Rec 2004;154:175-176.
24. Martinez-Subiela S, Ginel PJ, Ceron JJ. Effects of different glucocorticoid treatments on serum acute phase proteins in dogs. Vet Rec 2004;154:814-817.
25. Mischke R, Waterston M, Eckersall PD. Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. Vet J 2007;174:188-192.
26. Merlo A, Rezende BCG, Franchini ML, et al. Serum C-reactive protein concentrations in dogs with multicentric lymphoma undergoing chemotherapy. J Am Vet Med Assoc 2007;230:522-526.
27. Owens LN. Lymphoid and haematopoietic tissues (including lymphosarcoma of the skin). In: Owen LN, ed. TNM Classification of Tumors in Domestic Animals. Geneva, Switzerland: World Health Organization; 1980:46-47.
28. Mellanby RJ, Herrtage ME, Dobson JM. Treatment of canine lymphoma by veterinarians in first opinion practice in England. J Small Anim Pract 2002;43:198-202.
29. Alvarez FJ, Kisseberth WC, Gallant SL, Couto CG. Dexamthasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma. J Vet Intern Med 2006;20:1178-1183.
30. Chun R, Carrett LD, Vail D. Cancer Chemoterapy. In: Withrow Sj, DM Vail., eds. Withrow & MacEwen's Small Animal Clinical Oncology, 4th ed. St. Louis, Missouri: Saunders, Elsevier; 2007:163-193..
31. Jergens AE, Schreiner CA, Frank DE, et al. A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 2003;17:291-297.
32. Kjelgaard-Hansen M, Kristensen AT, Jensen AL. Evaluation of a commercially available enzyme-linked immunosorbent assay (ELISA) for the determination of C-reactive protein in canine serum. J Vet Med A Physiol Pathol Clin Med 2003;50:164-168.
33. Diggle P, Heagerty P, Liang K, Zeger S. Analysis of Longitudinal Data, 2nd ed. New York: Oxford University Press; 2002.
34. Otabe K, Sugimoto T, Jinbo T, et al. Physiological levels of C-reactive protein in normal canine sera. Vet Res Commun. 1998;22:77-85.
35. Ceron JJ, Eckersall PD, Martinez-Subiela S. Acute phase proteins in dogs and cats: current knowledge and future perspectives. Vet Clin Pathol 2005;34:85-99..
36. Hahn KA, Freeman KP, Barnhill MA, Stephen EL. Serum alpha 1-acid glycoprotein concentrations before and after relapse in dogs with lymphoma treated with doxorubicin. J Am Vet Med Assoc 1999;214:1023-1025.
37. Ogilvie GK, Walters LM, Greeley SG, et al. Concentration of α-1 acid glycoprotein in dogs with malignant neoplasia. J Am Vet Med Assoc 1993;203:1144-1147.
38. von Euler H, Einarsson R, Olsson U, et al. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. J Vet Intern Med 2004;18:696-702.
39. Nakamura N, Momoi Y, Watari T, et al. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. J Vet Med Sci 1997;59:957-960.
40. Gronowitz JS, Kallander FR, Diderholm H, et al. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 1984;33:5-12.
41. Hammer AS, Couto CG, Filppi J, et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160-166.
42. McMillan DC, Wotherspoon HA, Fearon KC, et al. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 1995;170:319-322.
43. Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-267.
44. Elahi MM, McMillan DC, McArdle CS, et al. The systemic inflammatory response predicts overall and cancer specific survival in patients with malignant lymphoma. Med Sci Monit 2005;11:CR75-CR78.